Ardelyx Receives a Buy from Cantor Fitzgerald

By Ryan Adsit

In a report released today, Mara Goldstein from Cantor Fitzgerald maintained a Buy rating on Ardelyx (NASDAQ: ARDX), with a price target of $12. The company’s shares opened today at $5.40, close to its 52-week low of $4.05.

According to, Goldstein is a 3-star analyst with an average return of 1.1% and a 46.6% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Karyopharm Therapeutics.

Ardelyx has an analyst consensus of Moderate Buy, with a price target consensus of $12.

The company has a one-year high of $16.30 and a one-year low of $4.05. Currently, Ardelyx has an average volume of 264.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ardelyx, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal, tract to treat gastrointestinal and cardio-renal diseases. The company’s products include Tenapanor, RDX002, RDX009 and RDX013.